Yearly Archives: 2017

­

Quark’s joint venture Riboquark announces the enrollment of the 1st ever Patient in China for a pivotal clinical trial with a siRNA drug candidate

November 13th, 2017|

RiboQuark Pharmaceutical Technology Co., Ltd., Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007.
Kunshan, China, 13/Nov/2017 – Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical […]

Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

November 7th, 2017|

Fremont, CA – November 7, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the […]

Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

November 4th, 2017|

 Fremont, CA – November 4, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, presented today at the late breaking plenary session of the American Society of Nephrology (ASN) / Kidney Week positive results from a Phase 2 clinical study, […]

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

November 1st, 2017|

Fremont, CA – November 1, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that Phase 2 data on its lead program QPI-1002 will be presented as an oral abstract at the American Society of Nephrology (ASN) […]

Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

October 9th, 2017|

FREMONT, Calif., Oct. 9, 2017 Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, is delivering an oral presentation at the 6th Annual RNAi China Conference in Jiangsu.

The presentation will summarize the preclinical efficacy data for inhaled small interfering RNA (siRNA) against an undisclosed […]

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

July 27th, 2017|

QPI 1002 Meets Primary & Multiple Secondary Endpoints
A statistically significant reduction in AKI incidence following cardiac surgery was demonstrated
First multicenter Phase 2 clinical study with an investigational drug for the prevention of AKI to meet primary endpoint
QPI-1002 appears to be well tolerated with no safety issues identified

Fremont, CA – July 27, 2017 – Today, Quark […]

Scientific Writer

March 8th, 2017|

 

Full-time or Contractor
Experienced in writing study reports for drug discovery programs including in vitro and in vivo Pharmacology studies
Reporting to CSO and working closely with Project Directors
M.Sc. in Biology or higher with at least 3 years industry experience
Experience in preparation of IND packages – advantage
Proficient in English (level of mother tongue)